Watching
AMN · AMN Healthcare Services
Updated ·
Against its published line
Above its line on the last close.
How to read this
The red mark is the published kill line — the price that would prove the thesis wrong. The dot is where the name closed on 21 October 2026; a dot left of the mark has closed through its line.
Distance is drawn on a square-root scale, so close calls get the room. Past 8% a row reads well clear, with a hollow dot to show the figure is off the drawn scale. Rows run tightest first.
Kill line
A daily close below $34, under the 18 September 2026 close of $34.26. A third-quarter revenue print at or below the $640 million low end of guidance would also break the case.
Not a pickResearch coverage at low conviction. A medium-or-higher call would open a pick on the scoreboard.
Catalyst (in 14 days)
How picks are graded →The thesis
AMN Healthcare Services is a hospital-staffing recovery now trading at a new high, and the third-quarter report on 5 November 2026 settles whether it holds. The shares closed at $37.66 on 14 October 2026, their 52-week high, after BMO Capital raised its target to $43 on 9 October 2026. The report has to show revenue inside the $640–655 million range management guided on 6 August 2026.
The narrative is maturing: the recovery is well known, the shares are up 7.6% over three months, and the newest analyst action on 9 October 2026 followed the price higher. The daily Relative Strength Index (14 days) reads 72.1, a level usually read as overbought. The shares now trade above the $36.14 average analyst target that an aggregator citing S&P Global showed on 2 October 2026.
BMO's $43 target is the highest cited among covering analysts in search summaries of its 9 October 2026 action. BMO kept its Outperform rating. Truist reiterated a Buy rating on 25 September 2026. UBS and Baird were Neutral at the last published actions in May 2026.
Bullish and bearish views on AMN Healthcare Services
The bull case on AMN Healthcare Services (AMN), in brief: Guidance points to continued growth. The bear case: Part of the second-quarter beat will not repeat.
Bull case
- Guidance points to continued growth. On 6 August 2026 AMN guided third-quarter revenue to $640–655 million, against a $618.2 million consensus, and Nurse and Allied growth of 9–11% year over year. Delivery would confirm the second-quarter result of $673.2 million revenue against $628.4 million expected.
- Profitability has returned. The second-quarter release showed net income of $21.2 million, or $0.53 diluted earnings per share.
- Search revenue is growing. Second-quarter search revenue rose 27% year over year, led by executive search and physician permanent placement (6 August 2026 release).
- The most bullish analyst keeps raising. BMO moved its target to $40 from $38 on 11 September 2026 and to $43 on 9 October 2026, each time keeping Outperform. Two raises in under a month show the estimate path is still rising at that firm.
Bear case
- Part of the second-quarter beat will not repeat. On the 6 August 2026 call, management attributed about $27 million of revenue and about 290 basis points of gross margin to non-recurring labor-disruption billing accruals and reserve adjustments. Third-quarter results must stand without that help.
- Growth is narrow. The 6 August 2026 outlook has Physician and Leadership Solutions revenue down 5–7% and Technology and Workforce Solutions down 11–13% in the third quarter. Only Nurse and Allied is guided to grow.
- Hospital hiring was slowing. The Bureau of Labor Statistics reported health-care employment up 13,000 in August, against a 12-month average gain of 32,000 (4 September 2026 release).
- Price has moved past consensus. The $37.66 close on 14 October 2026 sits above the $36.14 average target, and the same aggregator showed a Hold consensus across nine analysts on 2 October 2026. Targets will need to rise further for the price to have analyst support.
- Insider selling has occurred. Director Mark Foletta sold 3,681 shares for about $114,000 under a pre-arranged trading plan, per a Form 4 dated 15 June 2026.
Price setup
The last completed close was $37.66 on 14 October 2026, equal to the 52-week high. The Relative Strength Index of 72.1 shows buying has been heavy in recent weeks. The shares gained 7.6% over three months.
The 18 September 2026 close of $34.26 is the nearest prior reference low from the last note. A daily close under that level would reverse the recent advance. The shares are priced into an earnings date 22 days away, with the price at a high and the average target below it.
Crowding evidence is limited to what can be observed: the shares at a 52-week high, an overbought Relative Strength Index reading, a report due on 5 November 2026, and the small June director sale. No Form 4 filings were listed for the last 30 days.
Catalysts, next 30 days
- 5 November 2026, after market close: AMN reports third-quarter 2026 results and its fourth-quarter outlook. The company confirmed the release at about 4:15 p.m. Eastern and the call at 5:00 p.m. Eastern in its 7 October 2026 announcement. This is 22 days out and is the only event that tests the $640–655 million guide.
What would change the view
The case breaks if third-quarter revenue comes in at or below the $640 million low end of guidance, or if gross margin falls toward 28–28.5% without the second-quarter accruals. A fourth-quarter outlook below the third-quarter level, or Technology and Workforce revenue falling by more than the guided 11–13%, would also weaken it. On price, a daily close below $34, under the 18 September 2026 close of $34.26, would end the recent advance.
A third-quarter report that lands in the guided range with Nurse and Allied growth of 9–11% would support the case. It would still leave the shares above the last cited consensus target, so analyst targets would need to rise again.
What it trades with
AMN trades with hospital labor demand and contract-labor budgets, so monthly Bureau of Labor Statistics health-care payroll data and hospital margin commentary move it. Cross Country Healthcare is the closest listed travel-nurse peer and is being taken private by Knox Lane at $13.25 per share, which leaves few listed comparisons. Moves in small-cap health-care services and in the broader Russell 2000 index set the background.
Notes
- Reported results include lumpy labor-disruption billing accruals; Q2 2026 carried about $27M of revenue and about 290bps of gross margin from non-recurring items.
- Three reporting segments: Nurse & Allied, Physician & Leadership, Technology & Workforce. Only Nurse & Allied is guided to grow in Q3 2026.
- Cross Country Healthcare is being taken private by Knox Lane at $13.25 per share, so the listed travel-nurse peer set is thinner.
- Data aggregators often show stale or garbled AMN target and price figures; company filings and releases are the reference.
Related · shared themes
HUM
Humana Inc.
Humana's 2027 Star Ratings put 95% of its Medicare Advantage members in 4-star-or-better plans, up from about 20%, restoring 2028 quality-bonus revenue; the 6 November third-quarter report shows whether 2026 costs stay inside guidance.
MCK
McKesson Corporation
McKesson's fast-growing oncology and specialty-drug business keeps lifting earnings above guidance; its 4 November 2026 report shows whether it raises the $44.20–$45.00 fiscal 2027 EPS outlook again.
LFST
LifeStance Health Group, Inc.
LifeStance Health can meet third-quarter adjusted-EBITDA guidance of $49–59 million without improving on its $66.0 million second quarter. The 5 November 2026 report shows whether that holds and whether the $215–235 million full-year outlook rises.
STLN
Starling Oncology, Inc.
Starling Oncology's shift to capitated cancer-care contracts is lifting gross profit faster than revenue; the third-quarter 2026 report, expected around 9 November–12, shows whether adjusted EBITDA lands in the guided $500,000–$1.5 million range with full-year guidance intact.